New Task Order Request for Proposal Solicitation for PREVENT R&D Project Titled "KRAS Inhibition for Pancreatic Cancer Interception"
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Carrie Mills carrie.mills@nih.gov
- Brian Cholewa brian.cholewa@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health plans to issue a new task order request for proposal for the PREVENT R&D project "KRAS Inhibition for Pancreatic Cancer Interception," with an estimated solicitation release date of June 1, 2026 and an estimated award date of September 1, 2026. The work will systematically evaluate the safety and efficacy of KRAS inhibition in pancreatic ductal adenocarcinoma precursor lesions, PanIN and IPMN, using syngeneic and genetically engineered mouse models. IPMNs are detectable on imaging and progress stepwise from low-grade dysplasia to invasive cancer, and the forecast states that without funding, clinical trial testing of KRAS inhibition for pancreatic ductal adenocarcinoma would not be possible.
The estimated award value range is $1.5 million to $3.0 million, with no set-aside used and NAICS 541714 (Research and Development in Biotechnology, except Nanobiotechnology) assigned. Points of contact are Carrie Mills (carrie.mills@nih.gov) and Brian Cholewa (brian.cholewa@nih.gov), both at the National Institutes of Health.
Forecast text
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a 5-year survival rate of approximately 12% and a projected rise to the second leading cause of cancer-related death in the United States by 2030. Poor outcomes are largely driven by late-stage diagnosis and the absence of effective early detection or prevention strategies, highlighting a critical need for interventions targeting early disease. PDAC arises through well-characterized precursor lesions, primarily pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasms (IPMNs). IPMNs, which account for 10-15% of PDAC cases, represent a particularly suitable population for cancer interception due to their detectability on imaging and stepwise progression from low-grade dysplasia to invasive cancer. Although only a subset of IPMNs progress (~6%), their high prevalence translates into a substantial disease burden, with an estimated 1 million cases progressing to preinvasive or invasive PDAC over 10 years in the United States. Preclinical evidence supports KRAS inhibition as a strategy for cancer interception. The overall goal of this project is to systematically evaluate the safety and efficacy of KRAS inhibition in the PDAC precursor lesions, PanIN and IPMN, by employing syngeneic and genetically engineered mouse models. Should this task order not be funded, the testing of KRAS inhibition for pancreatic ductal adenocarcinoma in a clinical trial would not be possible.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast